---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-118180"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:58:12.967656+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TransCode reports Q3 2023 operating loss of $5.3M; cash runway only into Jan 2024

## Summary
- Cash $7.5M at Sept 30, 2023, vs $5.0M at Dec 31, 2022; expects runway only into Jan 2024.
- Operating loss $5.3M for Q3 2023 vs $4.3M in Q3 2022; R&D expense $3.3M, G&A $2.0M.
- Dosed first patient in Phase 0 trial of TTX-MC138 in advanced solid tumors; no adverse reactions reported.
- Closed public offering of 16.9M shares/pre-funded warrants at $0.51, gross proceeds ~$8.5M.
- Plans to file IND for Phase I trial of TTX-MC138 and pursue orphan drug designations.

## SEC filing metadata
- accession: 0001104659-23-118180
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465923118180/0001104659-23-118180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465923118180/tm2330726d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-118180
- JSON: https://secwatch.observer/filing/0001104659-23-118180.json
- Plain text: https://secwatch.observer/filing/0001104659-23-118180.txt

## Key facts
- Earnings Releases
  Transcode Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: TransCode Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465923118180/0001104659-23-118180-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.